ACHL - Achilles Therapeutics Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Achilles Therapeutics (ACHL)

Achilles Therapeutics (ACHL) possesses significant pricing power thanks to its PELEUS platform, which creates targeted vaccines against tumor nuclei. The growth-adjusted P/E ratio illustrates the asset's valuation trend, where the value of 0.00 serves as the current metric. The innovative method of training the immune system to attack rare mutations strengthens the company's scientific moat, establishing a robust foundation for combating severe forms of cancer.

ACHL: Achilles Therapeutics PLC PEG Multiple 07/04/2022 - 03/29/2025

Metric breakdowns and analytics for Achilles Therapeutics plc (ACHL)

- market value and analyst target forecast:
Fundamental company analysis:achillestx.com ACHL
Mass-produced product of achillestx.com

The high cost of developing personalized therapies at Achilles Therapeutics (ACHL) creates significant pressure on capital, making the upward trend of the P/E ratio a key indicator of business valuation efficiency. The PEG ratio allows for the identification of fundamental asset undervaluation when the value is below one, helping investors distinguish overvalued assets from promising "moonshots."